This protocol describes the steps required for the successful implantation of small cell neuroendocrine prostate cancer patient-derived xenograft (PDX) cells in the bone. Bone is one of the most common sites for the development of metastatic prostate cancer and its study is important for evaluating the tumor characteristics and response to therapy. This protocol can be used for the implantation of any tumor cell line in the bone.
Use of Radium223 in metastatic prostate cancer patient in treatment with denosumab: a potential trigger for Osteonecrosis of the jaw? A case report.